Regeneron Pharmaceuticals, Inc. (REGN) bonds
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/308% above fair value
$955.47+4.28 (+0.45%)
Close on Nov 13, 2026Market cap $98.84BP/E 21.1Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Total debt
$1.99B
Long-term debt
Net debt
-$1.67B
After $3.66B of cash
Implied interest rate
2.21%
FY2025 interest ÷ average debt
Interest coverage
81.7×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Notes and loans outstanding
As tagged in Regeneron Pharmaceuticals's 10-K for the period ended Dec 31, 2025
| Issue | Coupon | Matures | Carrying value |
|---|---|---|---|
| 1.750% Senior Notes due September 2030 | 1.75% | Sep 30, 2030 | $1.24B |
| 2.800% Senior Notes due September 2050 | 2.80% | Sep 30, 2050 | $741.40M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-K.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size |
|---|---|
| Letters of credit | $50.00M |
| Senior unsecured revolving credit facility | $750.00M |
See a number that looks wrong?